HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• HER-2 overexpression occurs in 20-25% of breast cancers, correlating with poor prognosis.
• Trastuzumab improves survival and reduces recurrence in HER-2 positive breast cancer but is limited by non-response and resistance.
• A new generation of targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, has been developed.

Purpose of the Study:

• To review current treatment strategies for HER-2 positive breast cancer.
• To focus on novel tyrosine kinase inhibitors (TKIs) for HER-2 positive breast cancer.
• To discuss the role of TKIs in combination with or after trastuzumab therapy.

Main Methods:

• Literature review of current HER-2 positive breast cancer treatment strategies.
• Analysis of emerging monoclonal antibodies and tyrosine kinase inhibitors targeting HER-2.
• Evaluation of combination therapies involving trastuzumab, chemotherapy, and novel agents.

Main Results:

• Trastuzumab demonstrates significant clinical benefits but faces challenges of intrinsic resistance and acquired resistance.
• New targeted agents include dual EGFR/HER-2 inhibitors (lapatinib, pertuzumab), anti-angiogenic drugs (bevacizumab), anti-mTOR agents (Temsirolimus), and anti-Hsp90 compounds (17-AAG).
• These agents show potential in combination with trastuzumab or chemotherapy, or as monotherapy, to overcome resistance and improve outcomes.

Conclusions:

• Despite trastuzumab's success, alternative and combination therapies are crucial for managing HER-2 positive breast cancer.
• Novel tyrosine kinase inhibitors represent a promising "second wave" of treatment, offering new avenues to target HER-2 signaling pathways.
• Further research into combination strategies and overcoming resistance mechanisms is essential for optimizing patient survival and treatment efficacy.